PRODUCTION OF RECOMBINANT BACULOVIRUSES

Abstract: This invention pertains to methods that facilitate production of recombinant baculoviruses that have been engineered for use as biological control agents. More specifically, this invention pertains to regulation of expression of genes encoded by recombinant baculoviruses in an insect cell or in an insect host.

Description: TITLE PRODUCTION OF RECOMBINANT BACULOVIRUSES BACKGROUND OF THE INVENTION Chemical insecticides are an integral component of modern agriculture, and are an effective means for reducing crop damage by controlling insect pests However, chemical agents are under continuous scrutiny due to the potential for environmental contamination, selection of resistant populations of agronomic pests, and toxicity to non- target organisms such as beneficial insects, aquatic organisms, animals and man As a result, alternative strategies for insect control are being sought that are effective and yet benign to non-target populations and the environment One of these strategies is to use microorganisms that are naturally occurring pathogens of target insect populations However, many candidate entomopathogens that would be promising insect control agents lack the properties of classical chemical insecticides such as host-specificity and rapid action that farmers and others in agribusiness have grown accustomed to Viruses from the family Baculoviridae are host- specific and have inert environmental properties, but lack the ability to rapidly neutralize a target population before significant crop damage takes place Fortunately, modern molecular biology provides the tools to produce recombinant baculoviruses engineered for use as biological control agents An attractive attribute of baculoviruses is their narrow host specificity These viruses infect only arthropods and possess relatively narrow host ranges even within a particular insect order Host specificity has been examined by electron microscopy, DNA hybridization and recombinant DNA technology (References 1-3) These studies indicate that the narrow host range is due, at least in part, to the inability of baculoviruses to transfer viral DNA into the mammalian cell nucleus Baculoviruses are divided into three subfamilies, including non-occluded baculoviruses (NOVs), granulosis viruses (GVs) and nuclear polyhedrosis viruses (NPVs) Although certain GVs and NOVs have been carefully studied, NPVs are the most thoroughly characterized ofthe baculovirus subfamilies Examples of NPVs include Autographa calif ormca NPV, Spodoptera exigua NPV, Helwthis armtgera NPV, Hehcoverpa zea NPV, Spodoptera frugtperda NPV, Trichoplusia m NPV, Mamestra brasstcae NPV, Lymantria dispar NPV, Spodoptera htturalts NPV, Syngrapha factfera NPV, Choristoneura fumiferana NPV, Anhcarsia gemmatahs NPV, and Helwthis virescens NPV Due in part to the availability of efficient cell culture systems and facile cloning vectors, NPVs have been used as eukaryotic expression vectors to synthesize desirable heterologous proteins (4,5) One virus in particular, Autographa cahfornica NPV (AcNPV), is the accepted model virus for introduction and expression of heterologous genes in baculovirus expression systems Although this virus is routinely used as an important in vitro means of providing for high yields of recombinant proteins in a eukaryotic expression system, thus affording appropriate post-translational modification of expressed proteins, AcNPV is capable of infecting many families of Lepidopteran insects that are important economic pests In spite ofthe potential practical advantages of baculovirus-based pest control agents, a variety of disadvantages have curtailed their use in modern agriculture The most significant barrier to more widespread use of these viruses in row-crop agriculture is the significant time delay between their application and effective control of crop damage caused by the host insects Unlike the rapid effects observed upon application of classical chemical insecticides, significant wild-type baculovirus-mediated insect control occurs only after in vivo populations of virus have reached levels high enough to compromise host activity This may occur as long as several weeks after infection in a cycle that involves two types of virions Following infection of insect cells, budded virions (BVs or extracellular virus, ECV) are produced upon movement of nucleocapsids to the plasma membrane These virions shed their nuclear-derived coat in the cytoplasm and bud through the cytoplasmic membrane into the hemocoel ofthe insect host This process leads to systemic infection ofthe host insect Later in the infection process, virions become occluded (occluded virions) by a protein matrix consisting substantially ofthe polyhedrin protein, thus forming polyhedral inclusion bodies (PIBs or occlusion bodies, OBs) These inclusion bodies are the orally infectious form ofthe virus and provide for horizontal transmission ofthe virus between insect hosts (6,7) Uninfected larvae feed on virus-contaminated substrates and ingest PIBs The proteinaceous matπx is solubilized by the action ofthe basic pH ofthe insect midgut found in many lepidopterous larvae The liberated virion nucleocapsids, containing the viral DNA genome, attach to and infect the epithelial cells ofthe larval midgut Typically, the infected insect will continue to develop and consume plant material while the virus exponentially propagates within the host Eventually, often after several weeks or longer have passed, the infected larvae will become fully involved and expire Through the use of recombinant DNA technology, NPVs have been genetically engineered to increase their rate of insect killing by either the introduction of genes directing the expression of insecticidal proteins or the deletion of genes from the viral genome (8-10) Both strategies yield biological insecticides that display more rapid insect control than wild-type, unengineered NPVs The most effective recombinant N Vs have been engineered to express insect-selective neurotoxins (1 1-18) The expressed toxins accelerate the onset of cytotoxicity, resulting in more rapid insect control These recombinant viruses kill their hosts in 20-30% less time than wild-type NPVs Baculoviruses destined for use as biological pest control agents must be produced in large quantities Mass-production of virus can be accomplished with standard in vitro insect cell culture systems or by in vivo production in infected insect larvae Yields of viral particles in either system are dependent on sufficient viral replication, which is in turn dependent on maintenance of healthy cells or insects Premature cell cytotoxicity or insect death will necessarily limit viral replication, thereby reducing the number of progeny virus produced Genetically modified baculoviruses, engineered to more rapidly neutralize target insects, may also result in less viral replication and result in lower yields of viral progeny per infected cell (in vitro) or per infected insect (in vivo) Thus, the means used to improve the efficacy of baculovirus-mediated insect control agents, making them viable alternatives or adjuncts to traditional chemical insecticides, may in fact defeat the economic viability of this pest control strategy Accordingly, a method for efficient production of insecticidal baculoviruses is needed that overcomes the barrier of premature cytotoxicity or premature killing ofthe host cell or insect SUMMARY OF THE INVENTION This invention pertains to methods that facilitate production of recombinant baculoviruses that have been engineered for use as biological control agents More specifically, this invention pertains to regulation of expression of genes encoded by recombinant baculoviruses in an insect cell or in an insect host In one embodiment, this invention pertains to a method for controlling expression of a gene encoded by the genome of a recombinant baculovirus in insect cell culture or in viable insects wherein said insect cells or insects have been genetically engineered to express a protein that regulates expression of a gene encoded by the baculovirus genome More particularly, the method for controlling expression of an insecticidal protein encoded by a chimeric gene in the genome of a recombinant baculovirus can be exploited for efficient production of recombinant insecticidal baculoviruses in insect cell culture or in viable insects, the steps of said method compπsing (a) constructing a recombinant insect cell having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression, (b) constructing a recombinant baculovirus expression vector having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein of step (a), said third nucleic acid fragment operably linked to a fourth nucleic acid fragment that encodes an insecticidal protein, (c) introducing the recombinant baculovirus expression vector of (b) stably into the recombinant insect cell of (a); and (d) maintaining the recombinant insect cell of (a) containing the recombinant baculovirus expression vector of (b) under conditions that support baculoviral replication; wherein expression ofthe regulatory protein of step (a) affects expression ofthe insecticidal protein of step (b) In another embodiment, this invention pertains to a method for controlling expression of an insecticidal protein encoded by a chimeric gene present in the genome of a recombinant baculovirus comprising: (a) constructing a recombinant insect cell having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression, (b) constructing a recombinant baculovirus expression vector having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein of step (a), said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein; (c) introducing the recombinant baculovirus expression vector of (b) into the recombinant insect cell of (a); and (d) maintaining the recombinant insect cell of (a) containing the recombinant baculovirus expression vector of (b) under conditions that support baculoviral replication wherein expression ofthe regulatory protein of step (a) affects expression ofthe insecticidal protein of step (b) In another embodiment, this invention pertains to a method for controlling expression of an insecticidal protein encoded by a chimeric gene present in the genome of a recombinant baculovirus comprising (a) constructing a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by said regulatory protein, said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (b) introducing the recombinant baculovirus expression vector of (a) into an insect cell; and 5 (c) maintaining the insect cell of (b) under conditions that support baculoviral replication wherein expression of said regulatory protein affects expression of said insecticidal protein In another embodiment, this invention pertains to a method for the production of insecticidal recombinant baculoviruses comprising (a) constructing a recombinant insect cell having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression, (b) constructing a recombinant baculovirus expression vector having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein of step (a), said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (c) introducing the recombinant baculovirus expression vector of (b) into the recombinant insect cell of (a), (d) maintaining the recombinant insect cell of (a) containing the recombinant baculovirus expression vector of (b) under conditions that support baculoviral replication wherein expression ofthe regulatory protein of step (a) affects expression ofthe insecticidal protein of step (b), and (e) collecting progeny viruses In another embodiment, this invention pertains to a method for the production of insecticidal recombinant baculoviruses comprising (a) constructing a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by said regulatory protein, said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (b) introducing the recombinant baculovirus expression vector of (a) into an insect cell, (c) maintaining the insect cell of (b) under conditions that support baculoviral replication wherein expression of said regulatory protein affects expression of said insecticidal protein; and (d) collecting progeny viruses In another embodiment, this invention pertains to methods for the production of insecticidal recombinant baculoviruses wherein the insect cell containing the recombinant baculovirus expression vector is maintained in an in vitro cell culture In another embodiment, this invention pertains to the methods for the production of insecticidal recombinant baculoviruses wherein the insect cell containing the recombinant baculovirus expression vector is maintained within an intact, living insect In another embodiment, this invention pertains to a method for the production of insecticidal recombinant baculoviruses comprismg (a) constructing a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a tetracycline transactivator protein and (2) a second chimeric gene comprising a third nucleic acid fragment encoding one or more tetracycline operator sites operably linked to a minimal promoter sequence, said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insect-selective neurotoxin, (b) introducing the recombinant baculovirus expression vector of (a) into an insect cell, (c) maintaining the insect cell of (b) in the presence of an effective amount of tetracycline or a tetracycline analog such that the tetracycline transactivator protein is unable to bind to the tetracycline operator sites present on said third nucleic acid fragment and thereby unable to induce gene expression directed by the minimal promoter sequence operably linked to said operator sites, and (d) collecting progeny viruses In another embodiment, this invention pertains to a recombinant insect cell containing a chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression directed by a second promoter In another embodiment, this invention pertains to a transgenic insect comprising one or more recombinant insect cells containing a chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression directed by a second promoter In another embodiment, this invention pertains to an insect cell or a transgenic insect comprising one or more recombinant insect cells, said insect cells containing a chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression directed by a second promoter, wherein the regulatory protein is the tetracycline transactivator protein In another embodiment, this invention pertains to a recombinant baculovirus expression vector having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter operably linked to a second nucleic acid fragment encoding an insecticidal protein, said first promoter affected by a regulatory protein expressed by a recombinant insect cell having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding said regulatory protein In another embodiment, this invention pertains to a recombinant baculovirus expression vector having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter operably linked to a second nucleic acid fragment encoding an insecticidal protein, said first promoter affected by a regulatory protein expressed by a recombinant insect cell having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding said regulatory protein, wherein said first nucleic acid fragment comprises one or more tetracycline operator sites operably linked to a minimal promoter In another embodiment, this invention pertains to a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by said regulatory protein, said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein. In another embodiment, this invention pertains to a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by said regulatory protein, said third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, wherein said regulatory protein is a tetracycline transactivator protein and wherein said third nucleic acid fragment comprises one or more tetracycline operator sites operably linked to a minimal promoter BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTINGS Figure 1 Quantification of recombinant and wild-type viral progeny as polyhedrin inclusion bodies (PIBs) from larvae ofH. virescens. "AcAalT/plO" represents recombinant baculoviruses wherein expression of AalT toxin is controlled by the late baculoviral p 10 promoter "AcLqhIT/pIO" represents recombinant baculoviruses wherein expression of LqhIT2 toxin is controlled by the very late baculoviral plO promoter "AcLqhlT/TEl" represents recombinant baculoviruses wherein expression of LqhIT2 toxin is controlled by the early baculoviral IE1 promoter "AcNPV" represents wild-type baculovirus Figure 2 Schematic representation of a tetracycline transactivator controllable system Figure 3 Plasmid map of TV3tTa Figure 4 Sequence ofthe synthetic oligonucleotides used to construct the LqhIT2 gene Oligonucleotide Lql (SEQ ID NO 4) encodes the Bombyxin signal peptide Oligonucleotides Lq 1 (SEQ LD NO 4) and Lq 10 (SEQ ID NO 13 ) were used as primers for PCR amplification ofthe synthetic gene Figure 5 Diagramatic representation ofthe strategy used to prepare the LqhIT2 gene Oligonucleotides Lql (SEQ LD NO 4) and LqlO (SEQ ID NO 13) (marked with an "X") served as amplification primers for PCR reactions Unique restriction enzyme cleavage sites are indicated Figure 6 Nucleotide (SEQ LD NO 14) and corresponding amino acid sequences ofthe LqhIT2 gene Lower case letters in the nucleotide sequence (nucleotides 1-57, encoding amino acids 1-19) indicate nucleotides encoding the Bombyxin signal peptide Figure 7 Map ofthe baculovirus expression vector TV3tTaTo-LqhIT2 Figure 8 Amino acid sequence (SEQ LD NO.21) of tetrLEl A The tetR and LE1A regions ofthe transactivator are indicated by lower case and capital letters, respectively The two amino acids residues indicated in bold (positions 208 and 209) have been added on as a result of extra restriction sites present in the sequence used to facilitate the in- frame insertion of tetR and LEI A Figure 9. Nucleotide sequences (SEQ LD NO.23 and 24) of the minimal p35 gene promoter of AcMNPV identifying the positions ofthe TATA box, and the early (E) and late (L) transcriptional start sites Restriction sites to be used for future insertion of foreign genes are also indicated Figure 10. Nucleotide sequences (SEQ ID NO 25 and 26) ofthe modified minimal p35 gene promoter of AcMNPV identifying the positions ofthe TATA box, and the early (E) and late (L) transcriptional start sites The single base-pair mutation in p35m is indicated in bold Restriction sites to be used for future insertion of foreign genes are also indicated Figure 11 Diagram ofthe region immediately upstream ofthe polyhedrin gene in transfer vectors pTV3(M)lq+ and pTV3(M)lq- The relative positions ofthe transactivator gene and a cassette containing tet operator sequences upstream ofthe p35/p35m minimal promoter and LqhIT are indicated Figure 12 Diagram ofthe region immediately upstream ofthe polyhedrin gene in transfer vectors ptTA(M)lq+ and ptTA(M)lq- The relative positions ofthe transactivator gene and a cassette containing tet operator sequences upstream ofthe p35/p35m minimal promoter and LqhIT are indicated. Applicant has provided 26 sequence listings in conformity with 37 C.F.R 1 821-1 825 and Appendices A and B ("Requirements for Application Disclosures Containing Nucleotides and/or Amino Acid Sequences") and in conformity with "Rules for the Standard Representation of Nucleotide and Amino Acid Sequences in Patent Applications" and Annexes I and II to the Decision ofthe President ofthe EPO, published in Supplement No 2 to OJ EPO, 12/1992 SEQ LD NO: l Bglll linker used in the construction of plasmid TV3tTa SEQ LD NO 2 Nucleotide sequence ofthe 407 bp Xho I to Bam HI restriction fragment from the plasmid pF43h, containing the minimal hGH promoter fused in tandem to seven tetracycline operator sequences SEQ LD NO 3 NotI linker used in the construction of plasmid ptetophGH SEQ LD NOs 4-13. Synthetic oligonucleotides used to construct the LqhIT2 gene Oligonucleotide Lql encodes the Bombyxin signal peptide Oligonucleotides Lql (SEQ LD NO 4) and LqlO (SEQ LD NO.13) were used as primers for PCR amplification ofthe synthetic gene SEQ LD NO 14 Nucleotide sequence ofthe synthetic DNA fragment encoding the Bombyxin signal peptide followed by the coding region for the LqhIT2 toxin SEQ LD NOs: 15 and 16 Nucleotide sequences of PCR primers TETR1 and TETR2 used to amplify the tetR portion of tTA SEQ LD NO' 17 Nucleotide sequence of the tetracycline repressor gene (tetR) which was amplified by PCR using oligonucleotides TETR1 and TETR2 SEQ ID NOs.18 and 19. Nucleotide sequences of PCR primers LE1A1 and LEI A2 used to amplify a 454 bp fragment from plasmid pIElH/C corresponding to the first 145 amino acid residues of LEI . SEQ LD NO.20. Nucleotide sequence of the activation domain of LEI (IE1A) which was amplified by PCR using oligonucleotides LEI Al and LE1A2 SEQ LD NO .21. Amino acid sequence of tetrLE 1 A SEQ ID NO.22. Nucleotide sequence of the BamHI fragment containing the SV40 polyadenylation signal SEQ ID NOs 23 and 24 Nucleotide sequences of two complementary oligonucleotides, P35PRO1 (SEQ LD NO 23) and P35PRO2 (SEQ LD NO 24), that, when annealed, represent the p35 minimal promoter from -8 to -57 bp relative to the translation initiation codon ofthe p35 gene SEQ LD NOs 25 and 26 Nucleotide sequences of two complementary oligonucleotides, P35MPRO1 (SEQ LD NO 25) and P35MPRO2 (SEQ ID NO 26), that, when annealed, represent a modified p35 minimal promoter wherein a single base pair change has been incoφorated into the promoter sequence that eliminates the late TTAAG RNA start site DETAILS OF THE INVENTION Disclosed is a method to suppress the expression of insecticidal proteins by recombinant NPVs for in vivo and in vitro production purposes In one embodiment, a gene encoding a regulatory protein is stably integrated into the genome of an insect or insect cell that is a natural host for insect baculoviruses In turn, a regulatory sequence that is responsive to the regulatory protein is stably introduced into the genome of a baculovirus at one or more locations near a promoter and/or enhancer element that directs expression of a heterologous protein Upon introduction into the host (I e , infection ofthe transgenic insect or transfection of transgenic insect cells with the recombinant baculovirus), the regulatory protein expressed by the transgenic insect or insect cells will interact with the regulatory sequence present on the baculovirus genome and affect expression ofthe gene or genes that are controlled by that regulatory sequence Alternatively, both the gene encoding the regulatory protein operably linked to an inducible, repressible or viral promoter, and the gene encoding the heterologous gene of interest that is operably linked to regulatory sequences that are responsive to the regulatory protein are present in the recombinant NPV genome These recombinant viruses are then propagated in wild-type insects or insect cells In the presence of an appropriate inducer or repressor of gene expression ofthe regulatory protein, control of heterologous gene expression will be affected For example, a structural gene encoding the tetracycline (tet) repressor protein that is under the control of a constitutive promoter (e g , actin promoter) or a viral promoter (preferably a promoter derived from a nuclear polyhedrosis virus) can be inserted into the genome of a lepidopterous insect Regulatory sequences that are responsive to the tet repressor are introduced into the viral genome proximal to the promoter and/or enhancer regions that control expression of an insecticidal protein The tet repressor binds to the regulatory sequence(s) and prevents transcription ofthe gene encoding the insecticidal protein Lack of expression of this insecticidal protein will delay the onset of paralysis and death ofthe infected insect, and result in an increase in production of PLBs In similar fashion, this strategy can be used to control the expression of cytotoxic proteins or proteins that render the virus unstable, thus maximizing virus yields in insect cell culture systems In the context ofthe present disclosure, a number of terms and abbreviations shall be used "NPV" stands for Nuclear Polyhedrosis Virus, a baculovirus "Polyhedrosis" refers to any of several virus diseases of insect larvae characterized by dissolution of tissues and accumulation of polyhedral granules in the resultant fluid "PLBs" are polyhedral inclusion bodies "AcNPV" stands for the wild-type Autographa califormca Nuclear Polyhedrosis Virus "LqhIT2" represents the insect- selective neurotoxin derived from Lewrus quinquestriatus hebraeus "AalT" represents the insect-selective neurotoxin derived from Androctonus australis "AcLqhIT2" is a short-hand form representing AcNPV that has been genetically modified to harbor the gene encoding LqhIT2 under the transcriptional control ofthe baculovirus very late plO promoter "Expression" refers to the transcription and translation of a structural gene to yield the encoded protein As will be appreciated by those skilled in the art, structural gene expression levels are affected by the regulatory sequences (promoter, polyadenylation sites, enhancers, etc ) used and by the host cell in which the structural gene is expressed Suitable "regulatory sequences" refer to nucleotide sequences located upstream (5'), within, and/or downstream (3') to a structural gene The regulatory sequences control the transcription and/or expression ofthe coding sequences, potentially in conjunction with the protein biosynthetic apparatus ofthe cell These regulatory sequences include promoters, operators, enhancer elements, transcription termination sequences, and polyadenylation sequences "Regulatory proteins" are proteins that recognize and bind to regulatory sequences and thereby affect transcription and/or expression ofthe coding sequences Regulatory proteins may exhibit a negative effect on gene expression (i e , reduce or eliminate transcription and/or translation) and may therefore be referred to as "repressors" In contrast, certain regulatory proteins may exhibit a positive effect on gene expression (i e , initiate or increase transcription and/or translation) and may therefore be known as "activators", "transactivators" or "inducers" "Operator" refers to a regulatory sequence which is recognized by a regulatory protein that modifies the rate of transcription initiation at an adjacent promoter "Promoter" refers to the nucleotide sequences, generally found at the 5' end of a structural gene, which direct the initiation of transcription Promoter sequences are necessary, but not always sufficient, to drive the expression of a downstream gene Usually promoters drive transcription preferentially in the downstream direction, although promotional activity can be demonstrated (at a reduced level of expression) when the gene is placed upstream ofthe promoter Thus, in the construction of heterologous promoter/structural gene combinations, the structural gene is placed under the regulatory control of a promoter such that the expression ofthe gene is controlled by promoter sequences The promoter is positioned preferentially upstream to the structural gene and at a distance from the transcription start site that approximates the distance between the promoter and the gene it controls in its natural setting As is known in the art, some variation in this distance can be tolerated without loss of promoter function. "Minimal promoter" refers to an RNA polymerase class II promoter generally comprised of a sequence of DNA known as a TATA box that binds RNA polymerase and short stretches of surrounding DNA sequences that, in the absence of additional promoter or operator elements, is unable to support transcription initiation "Ubiquitous promoter" refers to a promoter which is active (i e , able to support transcription of its adjacent gene) in all tissues and organs ofthe organism "Inducible promoter" refers to a promoter whose function is controlled by the binding or release of particular intracellular trans-acting factors Inducible promoters are distinguished from constitutive promoters which are unregulated and so are continually active The "3' non-coding sequences" refer to the DNA sequence portion of a gene that contains a polyadenylation signal and any other regulatory signal capable of affecting mRNA processing or gene expression The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end ofthe mRNA precursor "Gene" refers to the entire DNA portion involved in the synthesis of a protein A gene embodies the structural or coding portion which begins at the 5 1 end from the translational start codon (usually nucleotides ATG) and extends to the stop (nucleotides TAG, TGA or TAA) codon at the 3' end It also contains a promoter region, usually located 5' or upstream to the structural gene, which initiates and regulates the expression of a structural gene Also included in a gene are the 3' non-coding sequences "Chimeric" gene refers to an artificial gene comprising heterogeneous regulatory and coding sequences. "Heterologous" gene refers to genes or parts of genes not normally found in the host organism but that have been introduced by gene transfer "Nucleic acid fragment" refers to nucleotide sequences that are identified with particular functions within a gene "Structural gene" is that portion of a gene comprising a DNA segment encoding a protein, polypeptide or a portion thereof, and excluding the 5' and 3' sequences involved in regulatory control of gene expression The structural gene may be one which is normally found in the cell or one which is not normally found in the cellular location wherein it is introduced, in which case it is termed a heterologous gene. A heterologous gene may be derived in whole or in part from any source known to the art, including a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA or chemically synthesized DNA A structural gene may contain one or more modifications in either the coding or the untranslated regions which could affect the biological activity or the chemical structure ofthe expression product, the rate of expression or the manner of expression control Such modifications include, but are not limited to, mutations, insertions, deletions and substitutions of one or more nucleotides The structural gene may constitute an uninterrupted coding sequence or it may include one or more introns which are not expressed and which are bounded by the appropriate splice junctions The structural gene may be a composite of segments derived from a plurality of sources, naturally occurring or synthetic The structural gene may also include fused genes which encode a fusion protein "Synthetic gene" refers to a DNA sequence of a structural gene that is chemically synthesized in its entirety or for the greater part ofthe coding region As exemplified herein, oligonucleotide building blocks are synthesized using procedures known to those skilled in the art and are ligated and annealed to form gene segments which are then enzymatically assembled to construct the entire gene As is recognized by those skilled in the art, functionally and structurally equivalent genes to the synthetic genes described herein may be prepared by site-specific mutagenesis or other related methods used in the art The term "operably linked" refers to nucleic acid sequences on a single nucleic acid molecule which are associated so that the function of one is affected by the other For example, a promoter is operably linked with a structural gene when it is capable of affecting the expression of that structural gene (i e , that the structural gene is under the transcriptional control ofthe promoter) "Transfection" refers to stably introducing a DNA segment carrying a gene into an organism that did not previously contain that gene "Co-transfection" refers to simultaneous introduction of more than one DNA segment into an organism "Transgenic insect" refers to an insect comprised of cells that contain one or more transgenes "Transgenes" are genes that are introduced into the genome of a cell from which a transgenic organism develops and which remain in the mature organism, thereby directing expression of their encoded products in one or more cell types or tissues of said transgenic organisms "Chemically synthesized", as related to a sequence of DNA, means that the component nucleotides were assembled in vitro Manual chemical synthesis of DNA may be accomplished using well established procedures (19), or automated chemical synthesis can be performed using one of a number of commercially available machines It is understood that "an insect cell" refers to one or more insect cells maintained in vitro as well as one or more cells found in an intact, living insect "Baculovirus" refers to a group of viruses that only infect arthropods, a phylum that includes the genus Lepidoptera Insecticidal baculoviruses have great potential to provide an environmentally benign method for agricultural insect pest control However, improvements to efficacy are required in order to make these agents competitive with current chemical pest control agents One approach for making such improvements is through genetic alteration ofthe virus For instance, it may be possible to modify the viral genome in order to improve the host range ofthe virus, to increase the environmental stability and persistence ofthe virus, or to improve the infectivity and transmission ofthe virus In addition, improving the rate at which the virus acts to compromise the infected insect would significantly enhance the attractiveness of insecticidal baculoviruses as adjuncts or replacements for chemical pest control agents One method for increasing the speed with which the virus affects its insect host is to introduce into the baculovirus foreign genes that encode proteins that are toxic to the insect wherein death or incapacitation ofthe insect is no longer dependent solely on the course ofthe viral infection, but instead is aided by the accumulation of toxic levels of the foreign protein The results are insecticidal recombinant baculoviruses Many arthropods produce a mixture of insecticidal proteins referred to as venom These toxic substances are synthesized in specialized glandular tissues, which, when directed by a stinging or piercing apparatus, are capable of paralyzing the arthropod's prey Small, slow moving or stationary arthropods have adapted a strategy to instantaneously paralyze their prey by utilizing neurotoxic components ofthe venom at very low concentrations These components or neurotoxins interfere with the function of insect nervous tissues through efficient competition for certain receptor sites Many of these neurotoxins are polypeptides. These have been divided into different classes based on their host specificity and mode of action (20) For example, neurotoxic peptides isolated from numerous species of scorpions have been divided into classes that affect arthropods and classes that affect mammals Several ofthe arthropod-specific toxins have been identified as insect-selective peptides. For example, the Buthinae scorpions express two types of insect-selective neurotoxins that differ in their biological effects on target insects In the blowfly, those classified as excitatory toxins cause immediate, fast and reversible contractive paralysis due to induction of repetitive firing ofthe terminal branches ofthe motor neurons (21- 23) These toxins are single-chained polypeptides of approximately 70 amino acids and are cross-linked by four disulfide bridges The excitatory effect is attributed to an increase in the activatable action potential, sodium conductance, and a voltage- dependent slowing ofthe channel's closure AalT, a toxin produced from the venom of the scorpion Androctonus australis (24), was the first insect toxin isolated from these organisms that exhibited this excitatory action A second class of insect-selective neurotoxins are the depressant toxins, including BjIT2 (25), LqqIT2 (26) and LqhIT2 (27) These toxins are polypeptides of 60 to 65 amino acids which possess primary amino acid sequences that are distinct from the excitatory toxins. These toxins induce a slow, progressive paralysis and complete relaxation ofthe musculature ofthe insect. This activity is the result ofthe blockage of evoked action potentials (26, 28), and is attributable to the suppression ofthe activatable sodium conductance and depolarization ofthe axonal membrane. The methods and strategies used for preparation of recombinant baculoviruses that express heterologous genes are well known in the art (4, 5, 29) These methods of gene expression provide economical preparation of mammalian proteins in a eukaryotic expression vector system, in many instances yielding proteins that have achieved their proper tertiary conformation and formed the proper disulfide bridges necessary for activity. Commonly, the introduction of heterologous genes into the baculovirus genome occurs by homologous recombination between viral genomic DNA and a suitable "transfer vector" containing the heterologous gene of interest. These transfer vectors are generally plasmid DNAs that are capable of autonomous replication in bacterial hosts, affording facile genetic manipulation Baculovirus transfer vectors also contain a genetic cassette comprising a region ofthe viral genome that has been modified to include the following features (listed in the 5' to 3' direction): 1) viral DNA comprising the 5' region of a non-essential genomic region; 2) a viral promoter; 3) one or more DNA sequences encoding restriction enzyme sites facilitating insertion of heterologous DNA sequences; 4) a transcriptional termination sequence; and 5) viral DNA comprising the 3' region of a non-essential genomic region A heterologous gene of interest is inserted into the transfer vector at the restriction site downstream ofthe viral promoter. The resulting cassette comprises a chimeric gene wherein the heterologous gene is under the transcriptional control ofthe viral promoter and transcription termination sequences present on the transfer vector. Moreover, this chimeric gene is flanked by viral DNA sequences that facilitate homologous recombination at a non-essential region ofthe viral genome. Recombinant viruses are created by co-transfecting insect cells that are capable of supporting viral replication with viral genomic DNA and the recombinant transfer vector. Homologous recombination between the flanking viral DNA sequences present on the transfer vector and the homologous sequences on the viral genomic DNA takes place and results in insertion ofthe chimeric gene into a region ofthe viral genome that does not disrupt an essential viral function. The infectious recombinant virion consists of the recombined genomic DNA, referred to as the baculovirus expression vector, surrounded by a protein coat. In a preferred embodiment, the non-essential region ofthe viral genome that is present on the transfer vector comprises the region ofthe viral DNA responsible for polyhedrin production Most prefeπed is a transfer vector that contains the entire polyhedrin gene between the flanking sequences that are involved in homologous recombination Recombination with genomic DNA from viruses that are defective in polyhedrin production (due to a defect in the genomic copy ofthe polyhedrin gene) will result in restoration ofthe polyhedrin-positive phenotype This strategy facilitates identification and selection of recombinant viruses In another embodiment, baculoviral genomic DNA can be directly modified by introduction of a unique restriction enzyme recognition sequence into a non-essential region ofthe viral genome A chimeric gene comprising the heterologous gene to be expressed by the recombinant virus and operably linked to regulatory sequences capable of directing gene expression in baculovirus-infected insect cells, can be constructed and inserted directly into the viral genome at the unique restriction site This strategy eliminates both the need for construction of transfer vectors and reliance on homologous recombination for generation of recombinant viruses This technology is described by Ernst et al (30), and in WO94/28114 (31) Recombinant baculovirus expression vectors suitable for delivering genetically encoded insect-specific neurotoxins require optimal toxin gene expression for maximum efficacy A number of strategies can be used by the skilled artisan to design and prepare recombinant baculoviruses wherein toxin gene expression results in sufficient quantities of toxin produced at appropriate times during infection in a functional form and available for binding to target cells within the insect host One key to optimal mass production of recombinant NPVs is selection of an appropriate system to regulate gene expression Such a system preferably uses a repressor/operator element that suppresses transcription ofthe gene encoding the insecticidal activity Several repressor systems have been described that affect gene expression, including various inducible eukaryotic promoters (32-33) In addition, regulation of gene expression in eukaryotic cells can be achieved through the use ofthe lac repressor/operator inducer system of Escherichia coli Three approaches have been described (i) prevention of transcription initiation by properly placed lac operators at promoter sites (34-38), (ii) blockage of transcription mediated by RNA polymerase II during elongation by a lac repressor/operator complex (39), and (iii) activation of a promoter responsive to a fusion protein comprised ofthe lac repressor protein and the activating domain of virion protein 16 (VPI 6) of herpes simplex virus (40-41) However, due to slow and inefficient activation by the lac inducer isopropyl-β- D-thiogalactopyranoside (LPTG), this system has resulted in only moderate regulation (42) The present invention specifically concerns the construction of a system for regulatable gene expression employing the tetracycline (tet) operator-repressor system The tetracycline repressor is a DNA-binding protein with high affinity for the tet operator sequence The TnlO-encoded tet repressor regulates the expression of genes by binding to operator site(s) which overlap a promoter(s) (43,44) Tetracycline or an analog of tetracycline prevents the repressor from binding to its operator sequence, thus allowing RNA polymerase to bind to the promoter sequences and mediate mRNA transcription The tet operator-repressor system has been used successfully in plants to effectively control gene expression For instance, Gatz et al were able to use this system to reduce the activity of a constitutive promoter (cauliflower mosaic virus 35 S promoter, CaMV 35 S) by 500 fold in transgenic plants (45) Specifically, they generated a transgenic tobacco plant that synthesized 1 x IO 6 tet repressor molecules per cell Three tet operators were introduced into the vicinity ofthe TATA box ofthe CaMV 35S promoter Under normal physiological conditions gene expression was essentially inhibited However, addition of tetracycline prevented the repressor from binding to the operator sites, causing full derepression ofthe CaMV 35S promoter More recently, the tet operator-repressor system has been used to control gene expression in the protozoan parasite Trypanosoma brucei (46) Transgenic trypanosomes expressing the tetracycline repressor of E. coli exhibited inducer (tetracycline)-dependent expression of chromosomally integrated reporter genes under the control of a promoter bearing a tet operator Reporter expression could be controlled over a range of four orders of magnitude in response to tetracycline concentration; this far exceeds transcriptional regulation exhibited by other eukaryotic repression-based systems The instant invention controls expression of an insecticidal protein encoded by a recombinant virus genome Experimental evidence demonstrates a greater than approximately 10-fold decrease in yield of PLBs from insects infected with recombinant NPVs genetically engineered to express an insecticidal protein relative to PLB yield from insects treated with wild-type viruses (see Figure 1) Certain insecticidal proteins can have adverse effects on insect cells (e g , cytotoxicity) or can induce paralysis and death of an insect host These effects can result in a reduction in viral progeny and/or an unstable viral construct Suppressing the expression ofthe insecticidal protein would give the insect host cell the ability to support propagation of recombinant viruses to yields that approach yields of wild-type viruses This invention regulates toxin gene expression by several methods One method uses a tetracycline-controlled transactivator molecule (also referred to herein as "tetracycline transactivator protein") to control the promoter directing expression ofthe toxin gene Aspects of this tightly regulatable expression system are described in U S Pat No 5,464,758, incoφorated herein by reference, and by Gossen & Bujard (47, 48), and are depicted in Figure 2 The control element used for gene regulation is a fusion protein comprised ofthe tet repressor protein fused to the activating domain of virion protein 16 of heφes simplex virus (tTA) The invention also includes construction of a transgenic insect that constitutively expresses a repressor (or repressor-like) protein When a recombinant NPV containing a chimeric gene (comprised of an operably linked tet operator(s), promoter and toxin structural gene) is replicating in the transgenic host, the repressor binds to the operator(s) and inhibits expression ofthe toxin To construct this conditional regulatory system for gene transcription, two basic genetic manipulations are performed i) tet operator(s) fragments are inserted upstream ofthe toxin gene, preferably at a region which overlaps with the transcription initiation site and/or enhancer region, and ii) the repressor gene is stably engineered into the genome of a eukaryotic cell, preferably an insect or insect cell line The repressor may be placed under the control of a constitutive promoter (i e , actin) or baculovirus promoter (i e , LEI, plO or hybrid promoter) in order to drive expression ofthe repressor during infection ofthe host by recombinant virus Using a baculovirus promoter such as LEI, p 10, or polyhedrin, the repressor is expressed only at the time of viral infection This design provides for adequate expression ofthe repressor protein, since the virus provides the transcriptional machinery needed for viral replication The tet operator site(s) is placed into the viral genome proximal to the transcription start site and/or enhancer regions in order to block transcription ofthe heterologous protein (preferably an insecticidal protein) driven by the viral promoter High efficiency vectors for insertion of foreign genes into the insect genome are required for this strategy Mobile nucleic acid entities of various types have been identified in different insects (49) Insertion of mobile elements into DNA sequences can result in altered or disrupted gene expression which can be identified as mutant phenotypes Currently, high efficiency transformation of insects is achieved using the P- element based transformation vector system in Drosophila (50) However, these transformation vectors cannot be used for transformation of other insects (51) Therefore, alternative mobile genetic elements which have utility in other insects, including the high-efficiency transformation of lepidopterous insects, are required In addition, other transformation methods have focused on alternative delivery systems One such technique is "maternal microinjection" which involves the injection of DNA into eggs or ovaries within the gravid female This technique has been successfully used to introduce plasmid DNA sequences into the predatory mites Metaseiulus occidentals (52) and Amblyseius finlandicus (53) Recently, electroporation has also been reported to successfully deliver plasmid DNA to insect embryos (Keith Hughes, USDA, Fargo, ND, personal communication) One method to prepare a transgenic insect is to use a transposable-like element (TE) useful for introducing heterologous genes into the genome of lepidopteran insects These genetic elements facilitate construction of transgenic insects capable of expressing regulatory proteins that, in turn, control baculovirus gene expression One such TE is the mariner element which is widespread in arthropod genomes, and nearly ubiquitous in lepidopterous insects (55). The mariner element can be identified and prepared using degenerate primers derived from two conserved regions ofthe mariner transposase open reading frame. Recently, a mariner transposable element was isolated from the predatory mite, Metaseiulus occidentals (55) Using two inverse primers, the complete mariner element (Mocl) was sequenced and found to be 1284 bp in length, including 28 bp inverted terminal repeat sequences However, the Mocl mariner element contains numerous mutations, including frame shifts, and transposase activity can not be detected Based on these observations Mocl is considered to be an inactive transposable element However, an inactive mariner element is an attractive tool for introduction of exogenous DNA by homologous recombination, because it has accumulated numerous mutations, including deletions, insertions and stop codons. Insertion of exogenous DNA into such a mariner locus should be advantageous since the transposase gene is no longer viable and such exogenous DNA will remain stable The insertion ofthe tet repressor gene and a selectable marker (e.g , cyclodiene resistance gene - Rdl, (56, 57) containing a mariner fragment into a mariner locus in a lepidopterous insect occurs by homologous recombination Transformation is carried out by previously described microinjection techniques or newly developed electroporation protocols EXAMPLES The present invention is further defined in the following examples. It will be understood that the examples are given for illustration only and the present invention is not limited to use described in the examples. From the above discussion and the following examples, one skilled in the art can ascertain, and without departing from the spirit and scope thereof, can make various changes and modifications ofthe invention to adapt it to various usages and conditions. All such modifications are intended to fall within the scope ofthe intended claims EXAMPLE 1 Regulating expression of an insecticidal protein can also be achieved by incorporating the tTA and operator sites into the viral genome itself In this method, the control elements ofthe tetracycline resistance operon encoded in TnlO of E. coli were inserted into the AcNPV genome in order to regulate the expression of insecticidal protein(s) The tTA was placed under the control ofthe immediate early promoter LEI which expresses foreign genes immediately following infection by NPV The baculovirus transfer vector pAcP+F£lTV3 (provided by Dr. Donald Jarvis, Texas Agricultural Experiment Station, Texas A&M University, College Station, TX) was used for this construction and is a derivative ofthe baculovirus early promoter transfer vectors described in U.S Pat No 5,162,222 Initially, the tTA was excised from the plasmid pUHD15-l (obtained from Dr Robert Horlick, DuPont-Merck Pharmaceutical Co , Wilmington, DE) by the enzymes EcoRI and BamHI and inserted into the plasmid Bluescript SK±® (Stratagene, Menasha, WI) digested with EcoRI and BamHI Following ligation, plasmid DNA was transformed into E. coli DH5α (Gibco/BRL, Gaithersburg, MD), and presence ofthe insert was confirmed by restriction enzyme analysis Following confirmation ofthe tTA insert, an SV40 polyadenylation fragment (SEQ LD NO.22) (provided by Gary Chun, E I. du Pont de Nemours and Company) with BamHI restriction sites at the 5'- and 3'-ends was inserted at the BamHI restriction site in Bluescript SK±® directly downstream of the tTA The insert was confirmed for coπect orientation using an internal Hpal site (poly A) and an Xhol site found in the 3' end of the multiple cloning site of Bluescript SK±® The new plasmid containing the tTA and poly A fragment was digested with EcoRI and filled in with Klenow Polymerase, and a Bglll restriction site was added by incoφoration of a Bglll linker (SEQ LD NO 1) Following hgation, plasmid DNA was transformed into the E. coli DH5α The fragment containing the tTA and SV40 was then excised from this modified Bluescript SK±® plasmid with the restriction enzymes Bglll and NotI This fragment was ligated into the transfer vector pAcP+LElTV3 cut with Bglll and NotI This construct resulted in the insertion ofthe synthetic structural gene encoding tTA and polyadenylation fragment downstream ofthe baculovirus LEI promoter and the hr5 enhancer region Following ligation, plasmid DNA was transformed into the E. coli DH5α and resultant transformants were screened for possession of plasmids that contained a unique asymmetric site located at the 3' end ofthe tTA gene The new plasmid was labeled TV3tTa (Figure 3) The next step to construct a regulatory system for a recombinant baculovirus insecticide involved incoφorating a minimal promoter sequence and tetracycline operator sequences into the viral genome The restriction enzymes Xhol and BamHI were used to excise a minimal promoter (hGH) fused to tandem tetracycline operator sequences (7 tet operators) from the plasmid pF43h (SEQ ID NO 2, obtained from Dr R Horlick, DuPont-Merck Pharmaceutical Co ) This fragment was cloned into Bluescript SK±® that was previously digested with Xhol and BamHI Following ligation, plasmid DNA was transformed into the E. coli DH5α and positive clones were identified by restriction enzyme analysis This plasmid was then digested with the restriction enzyme Xhol (at 3 'end of multiple cloning site), filled in with Klenow Polymerase and relegated in the presence of a NotI linker (SEQ LD NO 3) Following ligation, plasmid DNA was transformed into E. coli DH5α and resultant transformants were screened by digestion with the restriction enzyme NotI The presence of an approximately 450 bp fragment following electrophoresis through a 2% agarose gel confirms the existence ofthe proper construct This plasmid is known as ptetophGH. Finally, a structural gene encoding an insect-selective neurotoxin, LqhIT2, is placed downstream ofthe minimal promoter into the BamHI cloning site. In order to prepare the LqhIT2 gene, ten oligonucleotides were designed (Figure 4, composite of SEQ LD NO:4-13) and synthesized by standard phosphoramadite chemistry These oligonucleotides were phosphorylated using Gibco/BRL (Gaithersburg, MD) kinase, annealed, and ligated using Gibco/BRL ligase following the scheme depicted in Figure 5, and employing the manufacturer's recommended protocols Ligated fragments were then amplified by employing the polymerase chain reaction (PCR) using Perkin-Elmer Cetus AmpliTaq ® Polymerase (Norwalk, CT) according to the manufacturer's protocol and the modifications described below Oligonucleotide Lql (SEQ LD NO 4) was used as the forward primer and oligonucleotide LqlO (SEQ LD NO 13) served as the reverse primer. The descriptions of these protocols are set out below in greater detail. Ten separate phosphorylation reactions (one for each oligonucleotide) were carried out. Two-hundred and fifty pmol of each oligonucleotide (SEQ ID NO:4-13) were placed in a 1.5 mL microcentrifuge tube Five uL of lOx kinase buffer, 1 uL of 1 mM ATP, 6 uL of kinase (Gibco/BRL, 10 units/uL), and a sufficient volume of water was added to each tube in order to bring the total reaction volume to 50 uL. The ten tubes were incubated at 37 °C for 1 h. Following incubation, 5 uL of each phosphorylated oligonucleotide (25 pmol) was placed into a single microcentrifuge tube, and the tube was placed into a dry heat blockset at 95 °C. The heat block was then turned off and allowed to cool to room temperature to facilitate annealing of phosphorylated oligonucleotides Fifty uL ofthe mixture of phosphorylated, annealed oligonucleotides were placed into a separate microcentrifuge tube along with 15 uL of 5X ligase buffer, 3 uL of 10 mM ATP, 4 uL of ligase enzyme (Gibco/BRL, 5 units/uL) and 3 uL of deionized water. This tube was incubated at 37 °C for 30 min and subsequently stored at room temperature overnight The synthetic nucleic acid fragment comprising the annealed and ligated oligonucleotides was amplified by PCR. Three PCR reactions were performed on varying dilutions of template DNA (comprising the phosphorylated, annealed and ligated oligonucleotides). The following reaction mix was employed for PCR reactions 61 5 uL of deionized water 10 uL of 10X PCR buffer (Perkin-Elmer Cetus) 2 uL each of dATP, dCTP, dGTP, dTTP (200 uM each) 0 5 uL of AmpliTaq® Polymerase (2 5 units/100 uL) Template DNA was diluted 1 100, 1 1,000 and 1 10,000 (v/v) with deionized water Eighty uL ofthe reaction mix was placed in each of three 0 5 mL microcentrifuge tubes Five uL ( 100 pmol) of oligonucleotide Lq 1 (SEQ LD NO 4) and 5 uL ( 100 pmol) of oligonucleotide LqlO (SEQ ED NO 13), (serving as the forward and reverse PCR primers, respectively), was added to each tube Ten uL of appropriately diluted template was added to each tube PCR reactions were carried out using a Perkin-Elmer DNA Thermocycler® programmed to carry out the following amplification protocol STEP 1 (1 cycle) 96 °C 3 minutes 75 °C 3 minutes STEP 2 (25 cycles) 95 °C 30 seconds 75 °C 2 minutes STEP 3 (1 cycle) 95 °C 30 seconds 75 °C 5 minutes Products resulting from amplification were analyzed by electoφhoresis through a 2% agarose gel An amplified fragment of approximately 300 base pairs was observed for each reaction Following PCR amplification ofthe LqhIT2 gene and flanking regions, the 300 bp band was isolated from a 2 0 % agarose gel and purified using a SpinBind® DNA recovery system (FMC, Rockland, ME) according to the manufacturer's protocol The isolated fragment was digested with BamHI in order to create cohesive 5' and 3' ends of the synthetic oligonucleotide containing the LqhIT2 gene and signal sequence (Figure 6, SEQ LD NO 14) The digested fragment was then inserted into the pTZ-18R plasmid (Pharmacia, Piscataway, NJ) at the BamHI cloning site using standard molecular cloning techniques Following transformation of E. coli DH5αMCR, isolated colonies were chosen and plasmid DNA was prepared Eight positive clones were identified and sequenced with the commercially available forward and reverse primers of pTZ-18R One clone (No 16) was found to contain the coπect sequence encoding for synthetic gene and signal sequence The resulting plasmid (pTZ-18RLq) contained two BamHI restriction sites, one site near the 5' end ofthe toxin gene and the other site following the stop codon pTZ-18RLq plasmid DNA was prepared according to standard protocols, and was digested with BamHI to release the inserted 300 base pair fragment containing the LqhIT2 gene and signal sequence This fragment was separated from vector sequences by electrophoresis through a 1.2 % agarose gel, and purified using a SpinBind® DNA recovery system The isolated fragment was then inserted into the BamHI cloning site of ptetophGH using standard molecular cloning techniques Following transformation into E. coli DH5αMCR, isolated colonies were chosen and plasmid DNA was prepared This plasmid was then digested with the restriction enzyme NotI, liberating a 750 bp fragment that was isolated from a 2.0 % agarose gel and purified using a SpinBind® DNA recovery system This fragment contains the tet operator sites, minimal hGH promoter and LqhIT2 gene/leader sequence The isolated and digested fragment was then inserted into the new baculovirus transfer vector, TV3tTa (supra), at the NotI cloning site, using standard molecular cloning techniques Following transformation into E. coli DH5αMCR, isolated colonies were chosen and plasmid DNA was analyzed by restriction enzyme analysis Several colonies containing the NotI fragment were isolated, propagated, and plasmid DNA was prepared for cotransfection. The new transfer vector is labeled TV3tTaTo-LqhIT2 (see Figure 7) Spodoptera rugiperda cells (Sf-9) were propagated in ExCell ® 401 media (JRH Biosciences, Lenexa, KS) supplemented with 3 0 % fetal bovine serum Lipofectin® (50 μL at 0 1 mg/mL, Gibco/BRL) was added to a 50 μL aliquot of TV3tTaTo-LqhIT2 (500 ng) and linearized polyhedrin-negative AcNPV (2 5 μg, Baculogold® viral DNA, Pharmigen, San Diego, CA) Sf-9 cells (approximate 50% monolayer) were co-transfected with the viral DNA/transfer vector solution The supernatant fluid from the co-transfection experiment was collected at 5 days post-transfection and recombinant viruses were isolated employing standard plaque purification protocols, wherein only polyhedrin-positive plaques are selected (6) Isolated plaques were picked and suspended in 500 μL of ExCell® media supplemented with 2 5% fetal bovine serum. Sf-9 cells in 35 mM petri dishes (50% monolayer) were inoculated with 100 μL ofthe viral suspension, and supernatant fluids were collected at 5 days post infection These supernatant fluids were used to inoculate cultures for large scale propagation of recombinant viruses Expression of LqhIT2 encoded by the recombinant baculovirus AcTV3tTaTo- LqhIT2 is confirmed by immunoblot analysis and bioassay Sf-9 cells (50 mL) are infected with wild-type AcNPV (negative control), AcLqhIT2 (positive control), or AcTV3tTaTo-LqhIT2 In the absence of tetracycline or an analog, heterologous protein is expressed efficiently in AcTV3tTaTo-LqhIT2 -infected cells However, m the presence of tetracycline or an analog, the expression ofthe toxin is suppressed Subsequent additional studies are conducted using different concentrations of tetracycline added to the media in order to determine the ability ofthe substrate to effectively control the expression ofthe heterologous protein At several intervals post infection, infected cells are collected and growth media is removed by centrifugation of cell suspensions Spent culture media is decanted and the remaining cells are lysed with a Branson Sonifier® (Model 450) for 30 sec at setting 2 Cellular debris is then removed by centrifugation at 15,000 φm for 10 min in a refrigerated microcentrifuge (4 °C) Protein concentrations of infected cell sonicates are quantified using the BCA Protein Assay (Pierce, Rockford, LL) according to the manufacturer's instructions A standard curve is prepared based on known concentrations of Bovine Serum Albumin Samples and standards are incubated for 30 min at 37 °C, and the absorbence at 562 is measured with a spectrophotometer Protein concentrations are determined for each sample by linear regression analysis Individual proteins in quantified samples are separated by protein electrophoresis Samples are diluted to 3-4 mg/mL protein with deionized water Twenty-five μL of each sample are added to 75 μL of electrophoresis sample buffer (3 8 mL deionized H 2 O, 1 0 mL 0 5 M Tris-HCl, pH 6 8, 0 8 mL glycerol, 1 6 mL 10% (w/v) SDS, 0 4 mL β-mercaptoethanol, 0 4 mL 0 5% bromophenol blue) Molecular weight standards are prepared by diluting 1 μL of biotinylated protein molecular weight standards (Gibco) in 100 μL of sample buffer Samples and standards are heated at 95° C for 2 min Samples are loaded (20 μL/well) onto a 15% Mini-Protean II Tris-HCl Ready Gel® (Bio-Rad, Melville, NY) Electrophoresis running buffer (3 g Tris base, 14 4 g glycine, 1 0 g SDS in 1 L deionized H 2 O) is added to the assembled electrophoresis gel apparatus and samples are electrophoresised for approximately 1 5 h at 40 mA Following electrophoresis, separated proteins are transferred from the electrophoretic gel to a nitrocellulose filter by western blotting Blotter paper (3MM, Schleicher and Schuell, Keene, NH) and nitrocellulose (BA-S NC, Schleicher and Schuell) are cut to the approximate dimensions ofthe gel and soaked in western transfer buffer (1 1 6 g Tris base, pH 8 3, 5 8 g glycine, 0 74 g SDS, 400 mL methanol, 1 6 L deionized H 2 O) The blotter paper, nitrocellulose and gel are assembled in the following sequence. 3 sheets of blotter paper, gel, nitrocellulose, and 3 pieces of blotter paper This "sandwich" is placed in the transfer apparatus such that the gel is oriented towards the cathode and the nitrocellulose membrane towards the anode Proteins are transferred by applying a current to the transfer apparatus for 4 h at 60 mA Following transfer, the apparatus is disassembled and the nitrocellulose filter allowed to air dry Immunoblot analysis of transfeπed proteins proceeds by the following steps, all of which are performed on rotary shaker at room temperature Sites on the nitrocellulose membrane that are unoccupied by transfeπed proteins are blocked with 3% (w/v) gelatin dissolved in TTBS (20 mM Tris, 500 mM NaCl, pH 7 5, 0 05% Tween-20) by incubation for 30 min The blocking solution is removed and the membrane is rinsed in 100 mL TTBS for 5 min LqhIT2-specific rabbit polyclonal antibody (obtained from Dr Bruce Hammock, University of California, Davis, CA) is prepared by adding 10 μL rabbit antibody to 10 mL TTBS This primary antibody solution is applied to the blocked nitrocellulose filter and incubated for 1 h Following this incubation, the nitrocellulose filter is washed in 3 changes of 100 mL TTBS, each wash lasting 10 min The secondary antibody is prepared by adding 10 μL peroxidase conjugated goat anti- rabbit IgG (Sigma, St. Louis, MO) and 10 μL peroxidase-labeled streptavidin to 20 mL TTBS The nitrocellulose filter is incubated with this solution for 1 h Following this incubation, the filter is washed in 3 changes of 100 mL TTBS, each wash lasting 10 min Detection reagent (ECL Detection kit, Amersham, Arling Heights, LL) is applied to the nitrocellulose and incubated for 60 sec The detection reagent is drained from the filter, and the filter covered with Saran Wrap Signal from the nitrocellulose filter is detected by exposing the processed membrane to X-ray film (Kodak X-OMAT AR, Rochester, NY) for 2 - 10 sec Isolates that provide a positive immunoblot response near 7,000 Mr are considered positive for toxin gene The conditions described above for carrying out the immunoblot procedure were developed using native LqhIT2 toxin wherein the limit of detection was determined to be 15 ng toxin In experiments using infected cell sonicates, LqhIT2 toxin encoded by the recombinant baculovirus AcTV3tTaTo-LqhIT2 was not detected, suggesting that the amount of toxin expressed in infected cells and present in the tested samples was below the detection limit ofthe assay EXAMPLE 2 A new transactivator gene hybrid was constructed which contained the tetR gene fused in frame with the activation domain ofthe AcMNPV LE-1 gene The tetR gene portion of tTA was PCR amplified using the following oligonucleotide primers TETR1 5'-ATGTCTAGATTAGATAAAAG-3' (SEQ LD NO 15) TETR2 5'-AGATCTGGACCCACTTTACATTTAAG-3' (SEQ LD NO 16) The DNA template for this reaction was the plasmid TV3tTa The following reaction mix was employed for this PCR reaction 33 uL of sterile deionized H 2 O lO uL of 5X Taq buffer D (InVitrogen) 5 uL of 10X dNTP stock (2 5 mM of each dNTP) 1 uL of oligonucleotide TETR1 (SEQ ID 15)(100 pmol) 1 uL of oligonucleotide TETR2 (SEQ LD 16)(100 pmol) 1 uL of plasmid DNA TV3tTa (10 ng) 0.2 uL of AmpliTaq Polymerase (5 units/uL) PCR reactions were carried out according to the following amplification protocol STEP 1 (1 cycle) 95 °C 1 min 72 °C 4 min STEP 2 (30 cycles) 95 °C 30 sec 45 °C 30 sec 72 °C 30 sec STEP 3 (1 cycle) 95 °C 30 sec 45 °C 30 sec 75 °C 5 min The resulting 622 base pair product (SEQ ID NO 17) contains the tetR gene from +1 relative to the translational start codon (ATG) to + 616 base pairs of tTA An extra Bglll restriction site was incoφorated at the 5' end of the oligonucleotide TETR2 for future insertion ofthe LE-1 activation domain into this site Two oligonucleotide primers, LE1A1 5 '-CGGGATCCATGACGCAAATTAATTTTAACG-3 ' (SEQ LD 18),and LE1A2 5'-CCAGATCTTTAACCTTGTGAATTGTCCAAGTATTC-3' (SEQ LD 19), were used to amplify a 454 base pair fragment (SEQ LD NO 20) from plasmid pLElH/C (58) corresponding to the first 145 amino acid residues of LE-1 (LEI A) This region has been reported to represent the activation domain of LE-1 (59) A BamHI or a Bglll site (incoφorated at the 5' end of LEIAI and IE1A2, respectively) was added onto the ends of LEI A during amplification to facilitate an inframe insertion of LEI A with tetR (see below) Conditions for PCR amplification ofthe IE-1 activation domain were identical to those described above for the tetR gene Both PCR amplification products, tetR and LEI A, were cloned directly into the plasmid vector PCRII (Invitrogen, San Diego, CA) using the TA cloning kit (Invitrogen) resulting in plasmids ptetR and pLEl A, respectively Several potential clones of ptetR were digested with BamHI and Bglll to identify those clones in which tetR was flanked upstream by BamHI and downstream by Bglll The fidelity of both tetR and LEI A were confirmed by sequence analysis The final hybrid transactivator gene was constructed by digesting pLEl A with BamHI and Bglll and inserting the 454 bp fragment containing LEI A into ptetR linearized by partial digestion with Bglll Correct clones in which LEI A was inserted in the same orientation as tetR were identified based on digestions using BamHI and Bglll. Only those clones containing tetR inserted inframe with LEI A generated a 1080 base pair fragment The resulting plasmid, ptetRLEl A, contains a hybrid gene consisting ofthe tetR gene fused in frame with LEI A (SEQ LD NO 21, Fig 8) The junction between tetR and LEI A was confirmed by sequence analysis Also, a BamHI fragment containing the SV40 polyadenylation sequence (SEQ LD NO.22) was cloned immediately downstream ofthe tetRLEl A gene at the Bglll site In addition to switching the VPI 6 activation domain with the analogous domain from L I, another modification to the system included the substitution ofthe human growth hormone (hGH) minimal promoter by the AcMNPV p35 minimal promoter This promoter contains both early and late transcriptional elements but is predominantly an early promoter (60) Two complementary oligonucleotides (200 pmol), P35PRO1 (SEQ LD NO.23) and P35PRO2 (SEQ ID NO:24) were annealed in 10X ligase buffer (New England Biolabs Inc.) by heating to 100 °C for 5 min and gradually cooling to room temperature over a 1 h period. The resulting annealed products represent the p35 minimal promoter from -8 to -57 bp relative to the translation initiation codon ofthe p35 gene (Fig. 9) The oligonucleotides were designed such that after annealing to each other, the ends were compatible with Sstl; however, only the 3' end ofthe promoter actually regenerated a Sstl site after cloning into an Sstl site The p35 minimal promoter was cloned into the Sstl site ofthe plasmid ptetophGH resulting in the substitution ofthe p35 promoter for the hGH promoter, and placing the p35 minimal promoter under transcriptional regulation ofthe tetop sequences The correct orientation ofthe p35 promoter relative to the tetop sequences was confirmed by digestion with Sstl and sequence analysis. The resulting plasmid was named ptetopp35 Similarly, a modified p35 minimal promoter was constructed by annealing together, under identical conditions as above, another set of oligonucleotides, P35MPRO1 (SEQ LD NO.25) and P35MPRO2 (SEQ LD NO.26), to generate a p35 promoter in which a single base pair change has been incoφorated into the promoter sequence which eliminates the late TTAAG RNA start site (Fig 10). Removal ofthe late start site should bring expression of LqhIT2 or other heterologous genes under total transcriptional control of tetRLEl A and reduce the leakiness ofthe system that may result from transcription from the late start site at late times during infection. The modified p35 minimal promoter was cloned into the Sstl site of ptetophGH resulting in plasmid ptetopp35m. Both ptetopp35 and ptetopp35m contain unique BamHI and NotI sites for insertion of DNA downstream ofthe p35/p35m minimal promoters The LqhIT2 gene and leader sequence was isolated from pTV3tTaTo-LqhIT2 by digestion with BamHI and a 300 base pair fragment containing the LqhIT2 gene and leader sequence were subcloned into a unique Bglll site in both ptetopp35 and ptetopp35m. The resulting plasmids, ptetopp35Lq and ptetopp35mLq, now contain the LqhIT2 gene/leader sequence immediately downstream ofthe p35/p35m promoter Clones containing LqhIT2 in the correct orientation relative to the p35/p35m promoter were identified by digestion with Sstl. The tetopp35/p35mLq cassette was completed by inserting a 204 base pair BamHI fragment containing the SV40 polyadenylation signal sequence (SEQ ID NO: 22) An internal Hpal site was used to identify clones with the polyA signal sequence in the coπect orientation relative to LqhIT2. The final plasmid, ptetopp35/p35mLqA, was used to supply the tetop cassette for insertion into the final transfer vector. Transfer vectors designed to incoφorate tetRLEl A and ptetopp35/p35mLqA into the AcMNPV genome were constructed in two stages. First, the transfer vector pAcP+LElTV3 (provided by Dr. Donald Jarvis, Texas A & M University, College Station, TX) was digested with Bglll and NotI (in the multiple cloning site) to linearize the vector A 1.3 kilobase-pair BamHL/Notl fragment derived from ptetRLEl A was directionally cloned into these sites in pAcP+LElTV3 placing the transactivator gene under transcriptional control ofthe hr5/ie-l promoter Second, the tetopp35LqA or the tetopp35mLqA cassette was inserted into an unique NotI site regenerated during insertion of tetRLEl A into pAcP+LElTV3 This was accomplished by digesting the vector with NotI and using the large fragment of DNA polymerase I (Klenow) to fill in the 5'overhanging termini to generate blunt ends. Similarly, ptetopp35/p35mLqA was digested with Xhol and Sstll and a 0.8 kbp fragment containing the tetopp35/p35mLqA cassette was blunt-ended using T4 DNA polymerase This fragment was then inserted into the blunt-ended NotI site. Clones containing each cassette in both orientations relative to the tetRLEl A gene were chosen to generate recombinant virus to determine the effect of orientation on toxin gene expression These clones were designated either Lq+ or Lq- depending on whether the toxin gene was in the same or opposite orientation as the transactivator, respectively (Fig. 11). Consequently, four different transfer plasmids (pTV31q+, pTV31q-, pTV3Mlq+ and pTV3Mlq-) were constructed. In addition, transfer plasmids were also constructed in which the tetopp35/p35mLqA cassette replaced the tetop-hGH-Lq cassette in pTV3tTaTo-LqhIT2 such that the former cassette was now under transcriptional control ofthe original tetR- VP16 (tTA) transactivator system (Fig 12) These plasmids were constructed in a similar manner as that described for pTV3Lq+ and pTV3Lq-, and were used to ultimately compare the efficacy ofthe alternate transactivators in their ability to be down regulated by tetracycline. Specifically, the 0.8 kbp blunt-ended Xhol/Sstll fragment (see above) was cloned in both orientations into pTV3tTaTo-LqhIT2 after the vector was digested with NotI (which released the tetop-hGH-LqhIT2 cassette) and blunt-ended with Klenow. The resulting four transfer plasmids contain tetopp35LqA or tetopp35mLqA in both orientations relative to tTA These transfer plasmids were designated ptTAlq±, ptTAlq±, ptTA q± and ptTAMlq-. Recombinant viruses were generated by co-transfecting 1 ug of a specific transfer plasmid and 0.5 ug of BaculoGold™ viral DNA (Pharmingen, San Diego, CA) into approximately 1.0 X IO 6 Sf-9 cells using lipofectin (GIBCO/BRL, Gaithersburg, MD) Transfection supernatants were collected after 5-7 days post-transfection and used in standard plaque purification protocols Five to six different plaque isolates were selected from the first plaque assay, each plaque was purified an additional time, and the virus initially amplified by infection of about 1 0 X IO 6 Sf-9 cells in a 35 mm tissue culture dish The resulting virus stock was used to generate working stocks in 75 cm 2 tissue culture flasks The eight different recombinant viruses produced in this manner are found in Table 1 Table 1 Recombinant viruses expressing LqhIT2 under different transactivators Virus Characteristics 1 vTV31q+ Contains tet repressor-HR5 transactivator with the operator/p35/lq cassette in the same 5'-3' orientation 2 vTV31q- Same as (1) but with op/p35/lq in opposite orientation 3 vTV3Mlq+ Same as (1) but with a modified p35 promoter with late expression ablated 4 vTV3Mlq- Same as (3) but with lq cassette in opposite orientation 5 vtTAlq± Contains the tet repressor-VP16 transactivator (lq cassette in same 5'- 3' orientation) 6 vtTAlq- Same as (5) but with lq cassette in opposite orientation 7 vtTAMlq± Same as (5) but with the modified p35 promoter 8 vtTAMlq- Same as (7) but with lq cassette in opposite orientation The in vivo activity of selected isolates from a few of these recombinant viruses was evaluated in feeding assays using 3rd instar Helwthis virescens larvae to determine if active toxin was expressed during infection and if so, whether the presence of tetracycline or an analog (such as doxycycline or aureomycin) would increase the LT5 0 of the virus relative to untreated controls In preliminary studies several different treatments were evaluated to determine whether the antibiotic was efficiently absorbed in the insect midgut and if not, whether ingredients in the diet affected absoφtion, and whether absoφtion could be improved by direct injection of antibiotic into the insect or by topical application ofthe antibiotic 3rd instar H. virescens larvae were allowed to consume a diet plug contaminated with 2000 PIBs of vTV3Mlq+ for 24 h either in the presence or absence of 0 3% doxycycline ("Dc", Sigma Chemical Co , Cat No D9891) After 24 h, individual larvae were transfeπed to the corresponding uncontaminated diet until 40 h post-infection when larvae were treated in the following manner A maintained on the diet (either 0% or 0 3% Dc), B injected with 4 ul of a 0 3% solution of Dc in H 2 0, C maintained on 2% (w/v) agar + or - 0 3% Dc, or D topical application of 4 uL of 0 3% Dc in acetone In treatments A, B, and D, larvae were returned to their coπesponding diet after treatment. Insects were scored at various times post-infection for symptoms of paralysis The results of this assay are summarized in Table 2 and provide evidence suggesting that the LT 5 oS ofthe test virus are affected by Dc and that this effect is dependent on the route by which Dc is introduced into the insect. Table 2. Effects of doxycycline on the LT 50 of vTV3Mlq+ infected Heliothis virescens larvae. TREATMENT LT S0 (h) A 1 maintained on 0% diet 84-92 injected w/ 0.3% Dc 92-108 maintained on agar w/o Dc 84-92 topical application of 0.3% Dc 92-108 B 2 maintained on 0.3% diet 92 injected w/ 0.3% Dc 1 16-135 maintained on agar + 0.3 % Dc 135 topical application of 0.3% Dc 108-1 16 ' insects infected and maintained on 0% Dc diet insects infected and maintained on 0.3% Dc diet Insects infected with vTV3Mlq+ and maintained in the presence of Dc either by injection or feeding on agar died slower than control insects not exposed to Dc. This effect was especially strong in the agar treatments where the LT 50 was increased by 45 to 60 %. The in vivo activity of selected vtTAlq±, vtTAMlq-, and vTV3Mlq+ viruses was also determined using diet pill bioassays. Third instar H. virescens larvae were fed diet pills (volume of 50 uL) contaminated with 2000 PIBs (representing about 20 x LC 50 ) from vtTAlq±, vtTAMlq-, vTV3Mlq+, CG201, or AcMNPV (C6) for 24 h before those insects that had completely consumed their diet were transferred to untreated diet (soy flour/wheat germ insect medium (Bioserv, Cat. No. 9967) ) containing 0.3% (w/v) tetracycline (Sigma, Cat. No.T3258), 0.3% (w/v) doxycycline (Sigma, Cat. No. D9891), or 1% (w/v) aureomycin (Bioserve). The antibiotics were added to the molten diet once the temperature ofthe diet was below 50 °C. The amount of antibiotic used in the diet was selected to maximize exposure to the antibiotic without having an adverse effect on the insects (i.e., stunting). Insects were incubated at 28 °C and scored for symptoms of intoxication/viral infection at various times post-infection and the LT 50 of each virus was determined for each antibiotic treatment (Table 3) using the VISTAT/TLME-for Analysis of Time Response Data program (Boyce Thompson Institute at Cornell University, 1990) CG201 is a recombinant virus expressing LqhIT2 under hr5/ιe-l promoter control without the tetracycline transactivator system Table 3 LT 50 of recombinant transactivator viruses exposed to different tetracycline analogs Virus Treatment 1 LT 50 ' vtTAlq± 3 untreated 784 Aureomycin 950 Tetracycline 974 Doxycycline 885 vtTAlq± 4 untreated 882 Aureomycin 999 Tetracycline 969 Doxycycline 1054 vtTAlq± 6 untreated 666 Aureomycin 783 Tetracycline 874 Doxycycline 916 vtTAMlq- 2 untreated 895 Aureomycin 1137 Tetracycline 1172 Doxycycline 1138 vTV3Mlq+ 1 untreated 773 Aureomycin 853 Tetracycline 793 Doxycycline 819 vTV3Mlq+ 5 untreated 769 Aureomycin 823 Tetracycline 800 Doxycycline 759 CG201 untreated 526 Aureomycin 596 Tetracycline 584 Doxycycline 627 AcMNPV (C6) untreated 972 Aureomycin 1078 Tetracycline 1047 Doxycycline 975 1 all antibiotic treatments performed at 0 3% (w/v) except Aureomycin (1%) In general, antibiotic treatments increased the LT50S of all viruses, however, the effects of these antibiotics on vtTAlq± 6 and vtTAMlq- 2 were significantly more dramatic than CG201 and AcMNPV Specifically, these two viruses exhibited about a 30 to 40% increase in the time to kill in the presence of tetracycline or doxycycline relative to untreated control insects This difference represented a 2 to 3 fold increase over the difference observed with CG201 -infected insects Other viral isolates of vtTAlq± exhibited less dramatic increases in LT 50 values relative to CG201 This variability between isolates ofthe same recombinant virus is likely a result of subtle differences in the expression of both transactivator and toxin by each isolate and is a normal phenomenon observed by people using the baculovirus expression vector system For this reason several different plaque isolates for each recombinant were tested The poorest performing recombinants were those that contain LqhIT2 under transcriptional control ofthe modified transactivator, tetRLEl A (vTV3Mlq+) The significant decrease in the LTso s of these recombinants relative to wild-type AcMNPV suggests that while the tetRLEl A was able to transactivate LqhIT2 expression, expression was not repressed in the presence of antibiotic This may be due to unanticipated conformational changes to the tetR portion ofthe transactivator protein when the VPI 6 activation domain was replaced with the LEI activation domain that compromises the ability ofthe transactivator to interact with tetracycline or an analog In summary, the bioassay results with selected AcMNPV recombinants expressing LqhIT2 under control of a tetracycline-sensitive transactivator indicate that the LT 50 of the recombinant viruses can be extended considerably when infection occurs in the presence of an antibiotic which can interact with the transactivator to reduce/delay expression of an insect-selective toxin REFERENCES (1) Carbonell, L F , Klowden, M J, Miller, L K , J. Virol. (1985), 56, 153-160 (2) Carbonell, L F , Miller, L K , Appl. Environ. Microbiol. (1987), 53, 1412-1417 (3) Brusca, J , Summers, M , Couch, J , Courtney, L , Intervirol. (1986), 26, 207-222 (4) O'Reilly, D R , Miller, L K , Luckow, V A , (1992), Baculovirus Expression Vectors: A Laboratory Manual, W H Freeman and Company, New York (5) King, L A , Possee, R D , (1992), The Baculovirus Expression System, Chapman and Hall, London (6) Granados, R R , Lawler, K A , Virology (1981), 108, 297-308 (7) Vlak, J M , Rohrmann, G F , In Viral Insecticides for Biological Control, Maramorosch, K , Sherman, K E , Eds , Academic Press, New York, NY (1985), 489-542 O'Reilly, D R , Miller, L K , J. Virol (1990), 64, 1321-1328 O'Reilly, D R , Miller, L K , Science (1989), 245, 1110-1 112 O'Reilly, D R , MUer, L K , Biotechnol (1991), 9, 1086-1089 Carbonell, L F , Hodge, M R , Tomalski, M D , Miller, L K , Gene (1988), 73, 409-418 Merryweather, A T , Weyer, U , Haπis, M P G , Hirst, M , Booth, T , Possee, R D , J. Gen. Virol. (1990), 71, 1535-1544 Martens, J W M , Honee, G , Zuidema, D , Van Lent, J W M , Visser, B , Vlak, j M , Appl. Environ. Microbiol. (1990), 56, 2764-2770 Tomalski, M D , Miller, L K , Nature (1991), 352, 82-85 Tomalski, M D , Miller, L K , Biotech (1992), 10, 545-549 Maeda, S , Volrath, S L , Hanzlik, T N , Haφer, S A , Maddox, D W , Hammock, B D , Fowler, E , Virol (1991), 184, 777-780 Stewart, L M D , Hirst, M , Ferber, M L , Merryweather, A T , Cayley, P J , Possee, R D , Nature (1991), 352, 85-88 McCutchen, B F , Choudary, P V , Crenshaw, R , Maddox, D , Kamita, S G , Palekar, N , Volrath, S , Fowler, E , Hammock, B D , Maeda, S , Biotech (1991), 9, 848-852 Caruthers, M , in Methodology of DNA and RNA Sequencing (1983), Weissman (ed ), Praeger Publishers, New York, Chapter 1 Zlotkin, E , Phytoparasitica (1991), 19, 177-182 Walther, D , Zlotkin, E , Rathmayer, E , J. Insect Physiol. (1976), 22, pp 1187-1194 Zlotkin, E in Neuropharmacology and Pesticide Action (1986), Ford, Lunt, Raey & Usherwood (eds ), Ellis Horwood, England, pp 352-383 Zlotkin, E , Fishman, L , Gordon, D in Neurotox'88: Molecular Basis of Drug and Pesticide Action, (1988), Lunt (ed ) pp 35-47 Zlotkin, E , Rochat, H , Kupeyan, C , Miranda, F , Lissitzky, S , Biochimie (Paris) (1971), 53, pp 1073-1078 Lester, D , Lazarovici, P , Pelhate, M , Zlotkin, E , Biochem. Biophys. Acta. (1982), 707, pp 370-381 Zlotkin, E , Kaduri, D , Gordon, D , Pelhate, M , Martin, M , Rochat, H , Arch Biochem. Biophys. (1985), 240, pp 877-887 (27) Zlotkin, E , Eitan, M , Bindokas, V P , Adams, M E , Moyer, M , Burkhart, W , Fowler, E , Biochemistry (1991), 30, pp 4814-4821 (28) Zlotkm, E , Gurevitz, M , Fowler, E , Adams, M , Arch, of Insect Biochem. Physiol. (1993), 22, pp 55-73 (29) U S Pat No 4,745,051 (30) Ernst, W , Grabheπ, R , Katinger, H , Nuc. Acid Res (1994), 22, 2855-2856 (31 ) Patent Cooperation Treaty, Publication Number WO 94/28114 (32) Brinster, R L , Chen, H Y , Warren, R , Sarthy, A , Palmiter, R D , Nature (1982) 296, pp 39-42 (33) Mayo, K E , Warren, R , Palmiter, R D , Cell (1982) 29, pp 99-108 (34) Hu, M C -T , Davidson, N , Cell (1987) 48, pp 555-566 (35) Brown, M , Figge, J , Hansen, U , Wright, C , Jeang, K-T , Khoury, G , Livingston, D M , Roberts, T M , Cell (1987) 49, pp 603-612 (36) Figge, J , Wright, C , Collins, C J , Roberts, T M , Livingston, D M , Cell (1988) 52, pp 713-722 (37) Fuerst, T R , Fernandez, M P , Moss, B , Proc. Natl. Acad. Sci (1989) 86, pp 2549-2533 (38) Deutschle, U , Pepperkok, R , Wang, F , Giordano, T J , McAllister, W T , Ansorge, W , Bujard, H , Proc. Natl. Acad Sci. (1989) 86, pp 5400-5405 (39) Deutschle, U , Hipskind, R A , Bujard, H , Science (1990) 248, pp 480-483 (40) Labow, M A , Baim, S B , Shenk, T , Levine, A J , Mol. Cell. Biol (1990) 10, pp 3343-3356 (41) Baim, S B , Labow, M A , Levine, A J , Shenk, T , Proc. Natl. Acad Sci (\99l) 88, pp 5072-5076 (42) Wyborski & Short, Nucleic Acids Res. 19, pp 4647-4653 (43) Bertrand, K P , Postle, K , Wray, L V , Reznikoff, W S , Gene (1983) 23, pp 149-156 (44) Hillen, W , Schollmeier, K , Gatz, C , J. Mol. Biol. (1984) 172, pp 185-201 (45) Gatz, C , Kaiser, A , Wendenburg, R , Mol. Gen. Genet (1991) 227, pp 229-237 (46) Wirtz, E , Clayton C , Science (1995) 268, 1179 - 1182 (47) Gossen, M , Bujard, H , Proc. Natl. Acad. Sci. (1992) 89, pp 5547-5551 (48) W O Pub No 94/29442 (49) Mevel-Ninio, M , Mariol, M -C , Gans, M , (1989) (50) Rubin and Spradling ( 1983) (51) Handler et al (1993) (52) Presnail, J K , Hoy M A , Proc. Natl. Acad. Sc . (1992) 89, pp 7732-7736 (53) Presnail, J K , Hoy M A , Exp. Applied Acarology (1994) 18, pp 319-330 (54) Robertson, H M , Nature (1993) 362, 241-245 (55) Jeyaprakash, A , Hoy, M A , Insect Mol Biol. (1995) 4, pp 31-39 (56) ffrench-Constant, R H , Mortlock, D P , Shaffer, C D , Maclntyre, R J , Roush, R T , Proc. Natl. Acad. Sci. (1991) 88, pp 7209-7213 (57) ffrench-Constant, Steichen, J C , Ode, P J , Pest. Bio. Phys. (1993) 46, pp 73-77 (58) Passarelli, A L , and L K Miller, J. Virol. (1993) 67, pp 2149-2158 (59) Kovacs, G R , Choi, J , Guaπno, L A , and M D Summers, J. Virol. (1992) 66, pp 7429-7437 (60) Nissen, M S , and P D Friesen, J. Virol (1989) 63, pp 493-503 SEQUENCE LISTING (1) GENERAL INFORMATION: (l) APPLICANT: (A) NAME: E. I. DUPONT DE NEMOURS AND COMPANY (B) STREET: 1007 MARKET STREET (C) CITY: WILMINGTON (D) STATE: DELAWARE (E) COUNTRY: U.S.A. (F) ZIP: 19898 (G) TELEPHONE: 302-892-8112 (H) TELEFAX: 302-773-0164 (I) TELEX: 6717325 (li ) TITLE OF INVENTION: PRODUCTION OF RECOMBINANT BACULOVIRUSES (in) NUMBER OF SEQUENCES: 26 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.50 INCH DISKETTE (B) COMPUTER: IBM PC COMPATIBLE (C) OPERATING SYSTEM: MICROSOFT WINDOWS 3.1 (D) SOFTWARE: MICROSOFT WORD 6.0A (v) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/009,120 (B) FILING DATE: DECEMBER 22, 1995 (vii) ATTORNEY/AGENT INFORMATION: (A) NAME: FLOYD, LINDA AXAMETHY (B) REGISTRATION NUMBER: 33,692 (C) REFERENCE/DOCKET NUMBER: BA-9078-A (2) INFORMATION FOR SEQ ID NO:l: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) MOLECULE TYPE: DNA (genomic) (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 1: CAGATCTG 8 (2) INFORMATION FOR SEQ ID NO:2: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 407 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: CTCGAGTTTA CCACTCCCTA TCAGTGATAG AGAAAAGTGA AAGTCGAGTT TACCACTCCC 60 TATCAGTGAT AGAGAAAAGT GAAAGTCGAG TTTACCACTC CCTATCAGTG ATAGAGAAAA 120 GTGAAAGTCG AGTTTACCAC TCCCTATCAG TGATAGAGAA AAGTGAAAGT CGAGTTTACC 180 ACTCCCTATC AGTGATAGAG AAAAGTGAAA GTCGAGTTTA CCACTCCCTA TCAGTGATAG 240 AGAAAAGTGA AAGTCGAGTT TACCACTCCC TATCAGTGAT AGAGAAAAGT GAAAGTCGAG 300 CTCAACAGTG GGAGAGAAGG GGCCAGGGTA TAAAAAGGGC CCACAAGAGA CCAGCTCAAG 360 GATTCCAAGG CCGCGGCCCC GAATTCGAGC TCGGTACCCG GGGATCC 407 (2) INFORMATION FOR SEQ ID NO: 3: ( ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ll) MOLECULE TYPE: DNA (genomic) (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 3: AGCGGCCGCT 10 (2) INFORMATION FOR SEQ ID NO: : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 75 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: ACGATGAATT CGGATCCTAT GAAGATCCTC CTTGCTATTG CCCTTATGCT TAGCACCGTG 60 ATGTGGGTGA GCACC 75 (2) INFORMATION FOR SEQ ID NO: 5: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GACGGCTACA TCAAACGCCG CGACGGCTGC AAAGTGGCCT GCCTTATCGG C 51 (2) INFORMATION FOR SEQ ID NO: 6: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: AACGAGGGCT GCGACAAAGA GTGCAAAGCC TACGGCGGCA GCTACGGCTA C 51 (2) INFORMATION FOR SEQ ID NO: 7: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: TGCTGGACCT GGGGCCTCGC ATGCTGGTGC GAGGGCCTCC CCGACGACAA A 51 (2) INFORMATION FOR SEQ ID NO: 8 : (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: ACCTGGAAAA GCGAGACCAA CACCTGCGGC TAAGGATCCT CTAGAGTC 48 (2) INFORMATION FOR SEQ ID NO: 9: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) MOLECULE TYPE: DNA (genomic) ( ) SEQUENCE DESCRIPTION: SEQ ID NO: 9: CACCCACATC ACGGTGCTAA GCATAAGGGC AATAGCAAGG AGGATCTTCA TAGGATCCGA 60 ATTCATCGT 69 (2) INFORMATION FOR SEQ ID NO: 10: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: AAGGCAGGCC ACTTTGCAGC CGTCGCGGCG TTTGATGTAG CCGTCGGTGC T 51 (2) INFORMATION FOR SEQ ID NO: 11: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GTAGCTGCCG CCGTAGGCTT TGCACTCTTT GTCGCAGCCC TCGTTGCCGA T 51 (2) INFORMATION FOR SEQ ID NO: 12: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GTCGGGGAGG CCCTCGCACC AGCATGCGAG GCCCCAGGTC CAGCAGTAGC G 51 (2) INFORMATION FOR SEQ ID NO: 13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GACTCTAGAG GATCCTTAGC CGCAGGTGTT GGTCTCGCTT TTCCAGGTTT TGTC 54 (2) INFORMATION FOR SEQ ID NO: 14: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ll) MOLECULE TYPE: DNA (genomic) (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 14: ATGAAGATCC TCCTTGCTAT TGCCCTTATG CTTAGCACCG TGATGTGGGT GAGCACCGAC 60 GGCTACATCA AACGCCGCGA CGGCTGCAAA GTGGCCTGCC TTATCGGCAA CGAGGGCTGC 120 GACAAAGAGT GCAAGGCCTA CGGCGGCAGC TACGGCTACT GCTGGACCTG GGGCCTCGCA 180 TGCTGGTGCG AGGGCCTCCC CGACGACAAA ACCTGGAAAA GCGAAACCAA CACCTGCGGC 240 TAA 243 (2) INFORMATION FOR SEQ ID NO: 15: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: ATGTCTAGAT TAGATAAAAG 20 (2) INFORMATION FOR SEQ ID NO: 16: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: AGATCTGGAC CCACTTTACA TTTAAG 26 (2) INFORMATION FOR SEQ ID NO: 17: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 623 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (x ) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ATGTCTAGAT TAGATAAAAG TGATTAACAG CGCATTAGAG CTGCTTAATG AGGTCGGAAT 60 CGAAGGTTTA ACAACCCGTA AACTCGCCCA GAAGCTAGGT GTAGAGCAGC CTACATTGTA 120 TTGGCATGTA AAAAATAAGC GGGCTTTGCT CGACGCCTTA GCCATTGAGA TGTTAGATAG 180 GCACCATACT CACTTTTGCC CTTTAGAAGG GGAAAGCTGG CAAGATTTTT TACGTAATAA 240 CGCTAAAAGT TTTAGATGTG CTTTACTAAG TCATCGCGAT GGAGCAAAAG TACATTTAGG 300 TACACGGCCT ACAGAAAAAC AGTATGAAAC TCTCGAAAAT CAATTAGCCT TTTTATGCCA 360 ACAAGGTTTT TCACTAGAGA ATGCATTATA TGCACTCAGC GCTGTGGGGC ATTTTACTTT 420 AGGTTGCGTA TTGGAAGATC AAGAGCATCA AGTCGCTAAA GAAGAAAGGG AAACACCTAC 480 TACTGATAGT ATGCCGCCAT TATTACGACA AGCTATCGAA TTATTTGATC ACCAAGGTGC 540 AGAGCCAGCC TTCTTATTCG GCCTTGAATT GATCATATGC GGATTAGAAA AACAACTTAA 600 GATGTGAAAG TGGGTCCAGA TCT 623 (2) INFORMATION FOR SEQ ID NO: 18: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: CGGGATCCAT GACGCAAATT AATTTTAACG 30 (2) INFORMATION FOR SEQ ID NO: 19: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: CCAGATCTTT AACCTTGTGA ATTGTCCAAG TATTC 35 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 455 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: CGGGATCCAT GACGCAAATT AATTTTAACG CGTCGTACAC CAGCGCTTCG ACGCCGTCCC 60 GAGCGTCGTT CGACAACAGC TATTCAGAGT TTTGTGATAA ACAACCCAAC GACTATTTAA 120 GTTATTATAA CCATCCCACC CCGGATGGAG CCGACACGGT GATATCTGAC AGCGAGACTG 180 CGGCACGTTC AAACTTTTTG GCAAGCGTCA ACTCGTTAAC TGATAATGAT TTAGTGGAAT 240 GTTTGCTCAA GACCACTGAT AATCTCGAAG AAGCAGTTAG TTCTGCTTAT TATTCGGAAT 300 CCCTTGAGCA GCCTGTTGTG GAGCAACCAT CGCCCAGTTC TGCTTATCAT GCGGAATCTT 360 TTGAGCATTC TGCTGGTGTG AACCAACCAT CGGCAACTGG AACTAAACGG AAGCTGGACG 420 AATACTTGGA CAATTCACAA GGTTAAAGAT ACTGG 455 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 amino acids (B) TYPE: amino ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Met Ser Arg Leu Asp Lys Ser Lys Val lie Asn Ser Ala Leu Glu Leu 1 5 10 15 Leu Asn Glu Val Gly Ile Glu Gly Leu Thr Thr Arg Lys Leu Ala Gin 20 25 30 Lys Leu Gly Val Glu Gin Pro Thr Leu Tyr Trp His Val Lys Asn Lys 35 40 45 Arg Ala Leu Leu Asp Ala Leu Ala Ile Glu Met Leu Asp Arg His His 50 55 60 Thr His Phe Cys Pro Leu Glu Gly Glu Ser Trp Gin Asp Phe Leu Arg 65 70 75 80 Asn Asn Ala Lys Ser Phe Arg Cys Ala Leu Leu Ser His Arg Asp Gly 85 90 95 Ala Lys Val His Leu Gly Thr Arg Pro Thr Glu Lys Gin Tyr Glu Thr 100 105 110 Leu Glu Asn Gin Leu Ala Phe Leu Cys Gin Gin Gly Phe Ser Leu Glu 115 120 125 Asn Ala Leu Tyr Ala Leu Ser Ala Val Gly His Phe Thr Leu Gly Cys 130 135 140 Val Leu Glu Asp Gin Glu His Gin Val Ala Lys Glu Glu Arg Glu Thr 145 150 155 160 Pro Thr Thr Asp Ser Met Pro Pro Leu Leu Arg Gin Ala Ile Glu Leu 165 170 175 Phe Asp His Gin Gly Ala Glu Pro Ala Phe Leu Phe Gly Leu Glu Leu 180 185 190 Ile Ile Cys Gly Leu Glu Lys Gin Leu Lys Cys Glu Ser Gly Ser Arg 195 200 205 Ser Met Thr Gin Ile Asn Phe Asn Ala Ser Tyr Thr Ser Ala Ser Thr 210 215 220 Pro Ser Arg Ala Ser Phe Asp Asn Ser Tyr Ser Glu Phe Cys Asp Lys 225 230 235 240 Gin Pro Asn Asp Tyr Leu Ser Tyr Tyr Asn His Pro Thr Pro Asp Gly 245 250 255 Ala Asp Thr Val Ile Ser Asp Ser Glu Thr Ala Ala Arg Ser Asn Phe 260 265 270 Leu Ala Ser Val Asn Ser Leu Thr Asp Asn Asp Leu Val Glu Cys Leu 275 280 285 Leu Lys Thr Thr Asp Asn Leu Glu Glu Ala Val Ser Ser Ala Tyr Tyr 290 295 300 Ser Glu Ser Leu Glu Gin Pro Val Val Glu Gin Pro Ser Pro Ser Ser 305 310 315 320 Ala Tyr His Ala Glu Ser Phe Glu H s Ser Ala Gly Val Asn Gin Pro 325 330 335 Ser Ala Thr Gly Thr Lys Arg Lys Leu Asp Glu Tyr Leu Asp Asn Ser 340 345 350 Gin Gly (2) INFORMATION FOR SEQ ID NO: 22: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 205 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: GGATCCAGAC CATGATAAGA TACATTGATG AGTTTGGACA AACCACAACT AGAATGCAGT 60 GAAAAAAATG CTTTATTTGT GAAATTTGTG ATGCTATTGC TTTATTTGTA ACCATTATAA 120 GCTGCAATAA ACAAGTTAAC AACAACAATT GCATTCATTT TATGTTTCAG GTTCATTTTT 180 AGGTGTGGGA GGTTTTTTCG GATCC 205 (2) INFORMATION FOR SEQ ID NO:23: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (x ) SEQUENCE DESCRIPTION: SEQ ID NO:23: CTATAAATAT TCAACGTTGC TTGTATTAAG TGAGCATTTG AGCTTTACCA AGGATCCGCG 60 GCCGCAGCT 69 (2) INFORMATION FOR SEQ ID NO: 24: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GCGGCCGCGG ATCCTTGGTA AAGCTCAAAT GCTCACTTAA TACAAGCAAC GTTGAATATT 60 TATAGAGCT 69 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: CTATAAATAT TCAACGTTGC TTGTATTCAG TGAGCATTTG AGCTTTACCA AGGATCCGCG 60 GCCGCAGCT 69 (2) INFORMATION FOR SEQ ID NO: 26: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 69 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: GCGGCCGCGG ATCCTTGGTA AAGCTCAAAT GCTCACTGAA TACAAGCAAC GTTGAATATT 60 TATAGAGCT 69

Claims: CLAIMS 1 A method for controlling expression of an insecticidal protein encoded by a chimeric gene present in the genome of a recombinant baculovirus comprising (a) constructing a recombinant insect cell having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression, (b) constructing a recombinant baculovirus expression vector having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein encoded by the second nucleic acid fragment, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (c) introducing the recombinant baculovirus expression vector constructed in step (b) stably into the recombinant insect cell constructed in step (a), and (d) maintaining the recombinant insect cell created in step (c) under conditions that support baculovirus replication wherein expression ofthe regulatory protein encoded by the second nucleic acid fragment affects expression ofthe insecticidal protein 2 A method for controlling expression of an insecticidal protein encoded by a chimeric gene present in the genome of a recombinant baculovirus comprising (a) constructing a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (b) introducing the recombinant baculovirus expression vector of step (a) stably into an insect cell; and (c) maintaining the insect cell created in step (b) under conditions that support baculovirus replication wherein expression ofthe regulatory protein affects expression ofthe insecticidal protein 3 A method for the production of insecticidal recombinant baculoviruses comprising (a) constructing a recombinant insect cell having a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression, (b) constructing a recombinant baculovirus expression vector having a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein encoded by the second nucleic acid, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (c) introducing the recombinant baculovirus expression vector of step (b) into the recombinant insect cell of step (a), (d) maintaining the recombinant insect cell created in step (c) either in an in vitro cell culture or within an intact, living insect under conditions that support baculovirus replication wherein expression ofthe regulatory protein encoded by the second nucleic acid fragment affects expression ofthe insecticidal protein, and (e) collecting progeny viruses. 4 A method for the production of insecticidal recombinant baculoviruses comprising (a) constructing a recombinant baculovirus expression vector having (1) a first chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression and (2) a second chimeric gene comprising a third nucleic acid fragment encoding a second promoter that is affected by the regulatory protein encoded by the second nucleic acid fragment, the third nucleic acid fragment operably linked to a fourth nucleic acid fragment encoding an insecticidal protein, (b) introducing the recombinant baculovirus expression vector of step (a) into an insect cell; (c) maintaining the insect cell produced by step (b) either in an in vitro cell culture or within an intact, living insect under conditions that support baculovirus replication wherein expression ofthe regulatory protein encoded by the second nucleic acid fragment affects expression ofthe insecticidal protein encoded by the fourth nucleic acid fragment, and (d) collecting progeny viruses 5 The method of Claim 4 wherein in step (a) (i) the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding regulatory protein is a tetracycline transactivator protein, (ii) the second promoter encoded by the third nucleic acid fragment comprises one or more tetracycline operator sites operably linked to a minimal promoter sequence, (iii) the insecticidal protein encoded by the fourth nucleic acid fragment is an insect-selective neurotoxin, and wherein, in step (c) the conditions that support baculovirus replication comprise the presence of an effective amount of tetracycline or an analog of tetracycline such that the tetracycline transactivator protein is unable to bind to the tetracycline operator sites comprising the third nucleic acid fragment and thereby is unable to induce gene expression directed by the minimal promoter sequence operably linked to the tetracycline operator sites 6 A recombinant insect cell containing a chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression directed by a second promoter 7 A transgenic insect comprising one or more recombinant insect cells containing a chimeric gene comprising a first nucleic acid fragment encoding a first promoter, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding a regulatory protein capable of affecting gene expression directed by a second promoter 8 The recombinant insect cell of Claim 6 or the transgenic insect of Claim 7 wherein the regulatory protein is a tetracycline transactivator protein 9 A recombinant baculovirus expression vector having a chimeric gene comprising a first nucleic acid fragment encoding a promoter that is affected by the regulatory protein expressed by the recombinant insect cell of Claim 6, the first nucleic acid fragment operably linked to a second nucleic acid fragment encoding an insecticidal protein 10 The recombinant baculovirus expression vector of Claim 9 wherein the first nucleic acid fragment comprises one or more tetracycline operator sites operably linked to a minimal promoter.

Inventors: MCCUTCHEN BILLY F, MCCUTCHEN, BILLY, F.
Applicants: DU PONT, MCCUTCHEN BILLY F, E.I. DU PONT DE NEMOURS AND COMPANY, MCCUTCHEN, BILLY, F.
Application year: 1996
Main classification: C12N15
IPC codes: A01K67, A01N63, C07K14, C12N5, C12N7, C12N15